Clearmind Medicine Makes Clinical Progress in Alcohol Addiction Treatment Trialbenzinga_article·Aug 13 at 01:05 PMCMND+1.61%
Clearmind advances CMND-100 into alcohol use disorder patients after Phase I/II safety milestonePUBT·Aug 13 at 06:36 AMCMND+1.61%
Clearmind Advances CMND-100 to Alcohol Use Disorder Patients After Achieving Primary Safety Endpoint | CMND Stock NewsStockTitan·Aug 12 at 10:36 PMCMND+1.61%
Clearmind Medicine Announces Positive Permeation Results for Intranasal MEAI Formulation, Supporting Enhanced Nasal Retention Without Compromising Drug Delivery | CMND Stock NewsStockTitan·Aug 10 at 11:05 PMCMND+1.61%
Clearmind advances CMND-100 alcohol use disorder trial into patient testing after Phase I safety readoutPUBT·Aug 6 at 08:26 AMCMND+1.61%
Clearmind Medicine Signs Letter of Intent to Acquire 51% Majority Stake in EV Wireless Charging Solutions for Automated Parking Systems Company | CMND Stock NewsStockTitan·Aug 2 at 11:02 PMCMND+1.61%
Clearmind reports positive safety, tolerability in CMND-100 Phase I/II trial Part A dose escalationPUBT·Jul 30 at 07:34 AMCMND+1.61%
Clearmind Medicine Successfully Completes Part A of its FDA Regulated Phase I/II Trial | CMND Stock NewsStockTitan·Jul 27 at 10:47 PMCMND+1.61%
